Cargando…

Convalescent plasma trial shows no benefit

Detalles Bibliográficos
Autor principal:	Brown, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	In Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530874/ https://www.ncbi.nlm.nih.gov/pubmed/33009505 http://dx.doi.org/10.1038/s41577-020-00461-3

Ejemplares similares

Absence of pathogenic viruses in COVID‐19 convalescent plasma
por: Kandathil, Abraham J., et al.
Publicado: (2022)

Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization
por: Harvala, Heli, et al.
Publicado: (2022)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
por: Hueso, Thomas, et al.
Publicado: (2020)

Lessons learned from the use of COVID-19 convalescent plasma at Kaiser Permanente
por: Tse, Kevin, et al.
Publicado: (2022)

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
por: Biernat, Monika Maria, et al.
Publicado: (2021)

Production of anti‐SARS‐CoV‐2 hyperimmune globulin from convalescent plasma
por: Vandeberg, Peter, et al.
Publicado: (2021)

Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19
por: Dai, Weiqian, et al.
Publicado: (2020)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks
por: Noor, Rashed, et al.
Publicado: (2021)

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients
por: Gharbharan, Arvind, et al.
Publicado: (2021)

Detection of SARS‐CoV‐2‐independent immunoregulatory activity of COVID‐19 convalescent plasma
por: Brox, Regine, et al.
Publicado: (2021)

Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study
por: Omma, Ahmet, et al.
Publicado: (2021)

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
por: Bainbridge, Emma D, et al.
Publicado: (2021)

Heterogeneity in COVID‐19 Convalescent Plasma Clinical Trials
por: Müller‐Olling, Mirco, et al.
Publicado: (2021)

Risk–benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19
por: Dhanasekaran, Sivaraman, et al.
Publicado: (2020)

Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis
por: Bansal, Vikas, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors
por: Dada, Ashraf, et al.
Publicado: (2022)

Treatment for emerging viruses: Convalescent plasma and COVID-19
por: Brown, Bethany L., et al.
Publicado: (2020)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

The resurgence of convalescent plasma therapy
por: The Lancet Haematology
Publicado: (2020)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Clinical and immunological characteristics in COVID-19 convalescent patients
por: Su, Zhiying, et al.
Publicado: (2021)

Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction
por: Lamikanra, Abigail, et al.
Publicado: (2021)

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
por: Nurmi, Visa, et al.
Publicado: (2023)

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
por: Benner, Sarah E, et al.
Publicado: (2020)

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
por: Herman, Jonathan D., et al.
Publicado: (2022)

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
por: Park, Hyung, et al.
Publicado: (2022)

International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection
por: Murphy, Michael, et al.
Publicado: (2020)

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
por: Simonovich, Ventura A., et al.
Publicado: (2020)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

Serosurveys and convalescent plasma in COVID-19
por: Pérez-Cameo, Cristina, et al.
Publicado: (2020)

COVID-19 convalescent plasma transfusion
por: Langhi, Dante Mário, et al.
Publicado: (2020)

Evidence-based dosing of convalescent plasma for COVID-19 in future trials
por: Rijnders, Bart J.A., et al.
Publicado: (2022)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9r2eqlhebeilo8ruarr2rs11c6